On April 2, 2026, the White House imposed a 100 percent tariff on imports of patented pharmaceuticals and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. For the 17 named companies listed in Annex III of the proclamation, including AbbVie, Amgen, Eli Lilly, Johnson and Johnson, Merck, Novartis, Novo Nordisk, and Pfizer, the tariff takes effect on July 31, 2026. For every other pharmaceutical importer, the effective date is September 29, 2026. The onshoring plan criteria that would qualify a company for the reduced 20 percent rate have not yet been published in the Federal Register. Boards that have not formally addressed this issue are already behind schedule.
This is not a trade policy story that boards can delegate to the government affairs team and revisit in Q4. It is a material financial exposure question with a hard deadline, an active compliance pathway, and a retroactive penalty structure for companies that get the process wrong. The window for submitting and obtaining an approved onshoring plan is open now. The criteria for qualifying will emerge from the Federal Register shortly. That sequence means board action on strategic posture, financial modeling, and compliance governance is required before the plan criteria are even published.
What the Section 232 Pharmaceutical Tariff Actually Does
The proclamation applies a 100 percent ad valorem tariff to patented pharmaceutical products and their associated active pharmaceutical ingredients. Generic pharmaceuticals are excluded. U.S.-origin products are excluded. The scope covers patented drugs produced in countries that have not entered pharmaceutical-specific trade agreements with the United States.
The tariff structure is tiered. Companies that enter into onshoring agreements approved by the Secretary of Commerce qualify for a 20 percent rate, which holds until April 2, 2030, at which point it reverts to 100 percent regardless of onshoring progress. Companies that negotiate Most Favored Nation pricing agreements with the Secretary of Health and Human Services may qualify for a zero percent rate through January 20, 2029. Companies sourcing from strategic partner countries, including European Union member states, Japan, South Korea, Switzerland, and Liechtenstein, face a 15 percent rate. Companies that do nothing face 100 percent.
The exposure is not theoretical. As of 2025, approximately 53 percent of patented pharmaceuticals distributed in the United States were manufactured abroad, and 85 percent of patented active pharmaceutical ingredients were sourced from foreign suppliers. A 100 percent tariff applied to that supply chain represents a cost shock that, at scale, will restructure the economics of every affected product’s commercial model.
The Board-Level Decision Window
For the 17 Annex III companies, the tariff becomes operative in 101 days from today. The July 1, 2026 joint status report from the Secretary of Commerce and the Secretary of Health and Human Services to the President is due before the tariff even takes effect. That report governs the early shape of onshoring negotiations. Companies that have not demonstrated substantive engagement by that date are unlikely to receive favorable treatment in the report’s framing.
The Federal Register will publish onshoring plan criteria before the July 31 effective date. However, companies that wait for those criteria before beginning internal analysis will not have sufficient time to conduct supply chain mapping, model the financial impact of each tariff tier, assess their legal exposure to retroactive penalties, and submit a credible plan for Commerce approval. The criteria will describe what is required. The analysis required to respond to those criteria must already be underway.
The Annex III temporary reduced rate carries its own deadline trap. Even companies that secure onshoring plans will see their reduced 20 percent rate expire on December 31, 2027, at which point products revert to higher Annex I-B rates unless onshoring commitments have been fulfilled. The four-year window to complete domestic manufacturing transitions, running through April 2, 2030, is already contracting. Facility construction timelines, regulatory approvals for new manufacturing sites, and supply chain reconfiguration cannot be compressed to accommodate delayed board action.
The Governance Failure Scenario
The proclamation contains a provision that few companies have addressed publicly and that represents the most acute governance risk in the framework. If the Secretary of Commerce finds that a company engaged in fraud or deliberately misled the U.S. government in connection with its onshoring plan submissions or progress reports, the Secretary may impose tariffs both prospectively and retroactively. Retroactive tariff imposition on a large pharmaceutical company’s import volumes over months or years of plan execution would produce a liability event of extraordinary size.
That risk sits directly at the intersection of legal compliance and board oversight. Progress reports are required periodically and may be subject to external audit. The representations made in onshoring plan submissions must be accurate, verifiable, and consistent with the company’s actual capital allocation decisions. Boards that approve onshoring commitments as a tariff reduction strategy without establishing governance structures to monitor and verify compliance are exposing the company to a retroactive penalty that no financial model has priced in.
The SEC’s posture on tariff-related disclosures compounds this risk. Companies face heightened scrutiny regarding the timing, accuracy, and completeness of public disclosures concerning material regulatory exposures. A company that signs an onshoring agreement, reports reduced tariff exposure to investors, and then fails to fulfill onshoring milestones has created both a Commerce enforcement problem and a potential securities disclosure problem simultaneously.
The Governance Imperative
The board’s obligation here extends beyond financial oversight. A decision to pursue an onshoring plan is a strategic commitment that reallocates capital, restructures supply chains, and makes representations to a federal agency. A decision to pursue an MFN pricing agreement is a commercial commitment with pricing implications that flow directly into revenue and margin forecasts. A decision to absorb the 100 percent tariff is a decision that must be disclosed as a material risk and that will be examined in every subsequent earnings call and investor meeting.
None of these decisions can be made correctly by management alone, and none of them can be deferred until the criteria are published. The board must direct management to complete a full supply chain audit against the tariff scope, model the financial impact of each available pathway under realistic timelines, assess the compliance governance requirements for each onshoring or MFN pathway, and present a recommended posture with a board authorization request before the Federal Register criteria appear.
The White House has reported that Section 232 tariff pressure has already produced approximately 400 billion dollars in announced domestic pharmaceutical manufacturing investment commitments. That figure reflects companies that assessed the landscape and made binding decisions. It also reflects the competitive disadvantage now accruing to companies that have not.
The available pathways are real and navigable: onshoring plans with approved federal oversight, MFN pricing negotiations, strategic partner sourcing diversification, and product portfolio analysis to identify which products carry the most acute tariff exposure. Each pathway has a timeline requirement. The pathway analysis requires board authorization. The authorization requires a meeting. That meeting, for Annex III companies, needs to happen this week.